211 related articles for article (PubMed ID: 23982600)
41. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
[TBL] [Abstract][Full Text] [Related]
42. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
43. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
44. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
45. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
47. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
50. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
51. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
52. Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.
Plaza MJ; Handa P; Esserman LE
AJR Am J Roentgenol; 2017 Apr; 208(4):910-915. PubMed ID: 28140614
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast.
Lee AH; Happerfield LC; Millis RR; Bobrow LG
Br J Cancer; 1996 Sep; 74(5):796-801. PubMed ID: 8795584
[TBL] [Abstract][Full Text] [Related]
54. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
55. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma.
Imamura H; Haga S; Shimizu T; Watanabe O; Kajiwara T; Aiba M
Br J Cancer; 1999 Jan; 79(1):172-8. PubMed ID: 10408711
[TBL] [Abstract][Full Text] [Related]
57. Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; Orange C; McMillan DC; Mallon E; Doughty JC; Edwards J; Going JJ
Hum Pathol; 2013 Aug; 44(8):1688-95. PubMed ID: 23574778
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes.
Kim HM; Koo JS
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580398
[TBL] [Abstract][Full Text] [Related]
60. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
